Table 2.
Statistical associations between IDH2 protein expression and the clinicopathological factors in invasive breast cancer cohort
| Clinicopathological parameters | IDH2 expression |
χ2 (p value) |
|
|---|---|---|---|
| Low (N = 349) N (%) | High (N = 510) N (%) | ||
| Age (years) |
3.526 (0.060) |
||
| ≤ 50 | 113 (37) | 197 (63) | |
| > 50 | 234 (43) | 310 (57) | |
| Tumour size (cm) |
7.787 (0.005) |
||
| ≤ 2 | 199 (45) | 241 (55) | |
| > 2 | 148 (36) | 256 (64) | |
| Tumour grade |
41.664 (< 0.0001) |
||
| Low | 71 (55) | 59 (45) | |
| Moderate | 140 (51) | 135 (49) | |
| High | 138 (30) | 314 (70) | |
| Tumour stage |
1.723 (0.632) |
||
| Low | 224 (41) | 316 (59) | |
| Moderate | 98 (40) | 150 (60) | |
| High | 27 (39) | 42 (61) | |
| Nottingham Prognostic Index |
21.763 (< 0.0001) |
||
| Poor | 45 (33) | 93 (67) | |
| Moderate | 169 (37) | 293 (63) | |
| Good | 133 (53) | 120 (47) | |
| LVI status |
9.552 (0.002) |
||
| Negative | 250 (45) | 311 (55) | |
| Positive | 97 (34) | 192 (66) | |
| Nodal status |
0.262 (0.609) |
||
| Negative | 222 (41) | 315 (59) | |
| Positive | 125 (40) | 191 (60) | |
| Oestrogen receptor |
25.640 (< 0.0001) |
||
| Negative | 55 (26) | 158 (74) | |
| Positive | 292 (46) | 350 (54) | |
| Progesterone receptor |
18.100 (< 0.0001) |
||
| Negative | 111 (32) | 236 (68) | |
| Positive | 229 (47) | 262 (53) | |
| HER2 status |
9.627 (0.002) |
||
| Negative | 312 (43) | 415 (57) | |
| Positive | 28 (27) | 76 (73) | |
| Molecular classes |
33.632 (< 0.0001) |
||
| Luminal A | 109 (53) | 95 (47) | |
| Luminal B | 122 (44) | 158 (56) | |
| HER2 enriched | 28 (27) | 76 (73) | |
| Triple negative | 43 (28) | 112 (72) | |
| Basal phenotypes | |||
| Negative | 272 (43) | 366 (57) |
7.360 (0.007) |
| Positive | 63 (32) | 135 (68) | |
| Ki67 | |||
| Negative | 127 (47) | 142 (53) |
7.131 (0.008) |
| Positive | 156 (37) | 266 (63) | |
Significant p values are in bold